Merck To Discontinue Phase 3 Keynote-867 Trial Of Keytruda Plus Stereotactic Body Radiotherapy For Patients With Stage I Or II Non-small Cell Lung Cancer And Phase 3 Keynote-630 Trial Of Keytruda As Adjuvant Treatment Of Patients With High-risk Locally Advanced Cutaneous Squamous Cell Carcinoma Following Surgery And Radiation
Portfolio Pulse from Benzinga Newsdesk
Merck is discontinuing two Phase 3 trials involving Keytruda due to lack of efficacy and unfavorable risk/benefit profiles. The trials, KEYNOTE-867 and KEYNOTE-630, did not meet their primary endpoints and showed higher adverse events.
August 29, 2024 | 10:34 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Merck is discontinuing two Phase 3 trials of Keytruda due to lack of efficacy and unfavorable risk/benefit profiles. The trials did not meet primary endpoints and showed higher adverse events.
The discontinuation of two major Phase 3 trials suggests that Keytruda may not be as effective in these indications as hoped, potentially impacting Merck's future revenue from this drug. The higher adverse events also raise concerns about the drug's safety profile in these trials.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100